Lonza Group AG
F:LO3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Lonza Group AG (LO3) under the Base Case is 252.92 EUR per share.
Compared with the current market price of 293.9 EUR, the stock appears
Overvalued by 14% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Lonza Group Does
Lonza Group AG is a life sciences company that makes and supplies ingredients, materials, and manufacturing services used in medicines and other health products. It does not sell to ordinary consumers; instead, it works behind the scenes for drug makers, biotech companies, and healthcare customers that need help developing or producing complex products.
- Headquarters
- Switzerland CH
- Employees
- 20 000
- IPO date
- Apr 3, 2002
Lonza Group has no economic moat
Rival manufacturers can offer drugmakers alternative production facilities and technical expertise, so Lonza cannot rely on its size alone to keep competitors out. Its established capabilities help it compete, but do not give it exclusive access to customers or drug-manufacturing markets.
Read the full moat analysis
Earnings Waterfall
Lonza Group AG
What is the Intrinsic Value of one LO3 stock?
The intrinsic value for Lonza Group AG (LO3) under the Base Case is 252.92 EUR.
Is LO3 stock undervalued or overvalued?
Compared with the current market price of 293.9 EUR, the stock appears Overvalued by 14% .
